Lipodystrophy Congenital GeneralizedLIPTURNNCT07799012
Sexual Quality of Life in Female Patients With Lipodystrophy Syndromes or Turner's Syndrome: a Case-control Study
An observational study of Lipodystrophy Congenital Generalized and Lipodystrophy, Familial Partial, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
Trial summary
Turner syndrome (TS) and congenital lipodystrophy syndromes (LS) are rare conditions with major consequences on cardiometabolic health, fertility, and body morphology. Some physical changes are visible from childhood in women with TS and from puberty in women with LS. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Lipodystrophy Congenital Generalized, Lipodystrophy, Familial Partial, Turner Syndrome
- How many people
- 1,416 participants
- Where
- 1 siteFrance
- Study dates
- 1 Oct 2026to Mar 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: Adult women with genetically confirmed lipodystrophy syndromes [Congenital Generalized] or [Partial Familial] or Turner syndrome, and with at least one consultation in the participant centers.
Who may be able to join
- Cases:
- Female aged 18 or more
- Diagnosed with LS (Congenital Generalized Lipodystrophy or Familial Partial Lipodystrophy) or TS, diagnosis genetically confirmed
- Patients followed in one of the participating centers
- Adequate written and oral comprehension of the French language
- No objection to participate
- Control group:
- Constances cohort with volunteers representative of the French general population.
Who cannot join
- Not applicable
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Judith LEBLANC, Nurse, Associate professor SU contact
France1 site
Endocrinologie, Diabétologie et Médecine de la reproduction
Paris, 75012
Inès BELALEM, Nurse - Data Manager, PhDs, 00 33 149282401, Ines.belalem@aphp.fr
Sophie LAMOTHE, MD, Sophie.lamothe@aphp.fr
About this study
Official title: Sexual Quality of Life in Female Patients With Lipodystrophy Syndromes or Turner Syndrome: a Case-control Study
Turner syndrome (TS) and congenital lipodystrophy syndromes (LS) are rare conditions with major consequences on cardiometabolic health, fertility, and body morphology. Some physical changes are visible from childhood in women with TS and from puberty in women with LS. Frequently, body morphology constitutes the first symptom orienting the diagnosis.
In 2018, a systematic review identified 13 studies (4 randomised controlled trials, 1 case-control study, 4 cohort studies, 4 cross-sectional studies) assessing quality of life in women with TS and two observational studies in women with LS (1 cohort study, 1 cross-sectional study). These investigations suggested an impairment in the overall quality of life compared with the general population.
Read more
However, little data exists on sexual quality of life, which is influenced by various factors: biological, hormonal, developmental, psychological, relational and social determinants. In the context of these chronic conditions, with biological and hormonal determinants, sexual quality of life may be affected.
Only three observational studies assessing sexual quality of life with small sample sizes, including one ongoing study, have been identified. Data suggested a decrease in the sexual quality of life.
When integrated into women's care pathways, aesthetic care recommended in French national diagnostic and management plans may help improving body image in women with LS. The uptake of these treatments in line with the recommendations has never been assessed, nor have their costs.
This study aims to compare the sexual quality of life of women with TS or LS with that of the general population.
Read the detailed description
Turner syndrome (TS) and congenital lipodystrophy syndromes (LS) are rare conditions with major consequences on cardiometabolic health, fertility, and body morphology. Certain physical changes are visible from childhood in women with TS and from puberty in women with LS. Frequently, body morphology constitutes the first symptom orienting the diagnosis.
In 2018, a systematic review identified 13 studies (4 randomised controlled trials, 1 case-control study, 4 cohort studies, 4 cross-sectional studies) assessing quality of life in women with TS and two observational studies in women with LS (1 cohort study, 1 cross-sectional study). These investigations suggested an impairment in the overall quality of life compared with the general population.
However, little data exists on sexual quality of life, which is influenced by various factors: biological, hormonal, developmental, psychological, relational and social determinants. In the context of these chronic conditions, with biological and hormonal determinants, sexual quality of life may be affected.
Only three observational studies assessing sexual quality of life with small sample sizes, including one ongoing study, have been identified. Data suggested a decrease in the sexual quality of life.
In a 2013 cohort study of 26 sexually active women with TS, reduced arousal was found. A cross-sectional study involving 46 women with LS suggested that 42% of women were dissatisfied with their sex lives. A cross-sectional study comparing the sexual function of 99 women with TS and premature ovarian failure to that of 106 women with premature ovarian failure without TS showed that women with LS had less frequent sexual intercourse, a later age at first intercourse, a lower number of sexual partners and less frequent orgasms.
When integrated into women's care pathways, aesthetic care recommended in French national diagnostic and management plans may help improving body image in women with LS. The uptake of these treatments in line with the recommendations has never been assessed, nor have their costs.
This study aims to compare the sexual quality of life of women with TS or LS with that of the general population.
The hypothesis is that sexual quality of life is poorer in women with TS or LS than in the general population.
Perceptions of body image, the use of aesthetic care and their costs will also be described to assess the implementation of recommendations and to develop potential avenues for care or improvement, if necessary, in the management of these patients.
Sample size:
We aim to test two hypotheses concerning the two populations (LS and TS) compared with controls from the general population, for whom the proportion of sexual dissatisfaction is estimated at 27.5%. Assuming a proportion of dissatisfaction at least 20% higher in both patient groups, with a two-sided alpha of 2.5%, a power of 80%, and Fisher's exact test, 118 women with LS, 118 women with TS, and 590 + 590 matched controls (planned ratio 1:5) will be required, for a total of 1,416 participants.
The qualitative interviews will be proposed to 20 women (10 LS and 10 TS), selected purposively according to age, study center, and investigators' judgment.
Study procedures:
Quantitative phase:
An information sheet will be sent by post, accompanied by an explanatory letter from the patient's doctor, and a telephone consultation will be arranged with the study coordinator at each centre to document non-opposition from all patients meeting the inclusion criteria. A reflection period of 5 to 10 minutes will be allowed. The non-opposition will be recorded in the medical record.
Patients have a 14-day period to complete the questionnaires at home using an e-CRF. The time required to complete the questionnaires is estimated at approximately 30 minutes.
In the event of non-response, reminders will be sent by email on Day 15, followed by a telephone call on Day 21. Patients hospitalized or attending outpatient consultations in participating centres during the recruitment period will also be invited to participate, if they have not already completed the questionnaires.
Qualitative phase:
Following questionnaire completion, and approval of the study coordinator for the centre, an information sheet accompanied by an explanatory letter from the patient's doctor, will be sent by post to a sample of 20 women, and a telephone consultation will be arranged to invite them to take part in the qualitative study.
Semi-structured interviews of 45 minutes will be conducted remotely or in person during hospitalisations or outpatients' consultations in the Endocrinology Department, Saint Antoine Hospital, AP-HP, by the coordinating investigator within two months of documented non-opposition.
Study duration:
- Inclusion period: 14 months (quantitative phase: 9 months; qualitative phase: 5 months)
- Individual participation period: maximum of 2 months and 28 days (quantitative phase: maximum of 28 days; qualitative phase: maximum of 2 months)
- Total study duration: 16 months + 28 days
Number of centers: 3
- Keywords
- Lipodystrophy, Turner Syndrome, Sexual Health, Quality of Life, Body Image, Body Satisfaction, Body Dissatisfaction
- Medical subject headings
- Lipodystrophy, Familial Partial, Turner Syndrome, Lipodystrophy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Lipodystrophy syndromes group | 118 patients with lipodystrophy syndromes | |
| Turner syndrome group | 118 patients with Turner syndrome | |
| General population (Constances' cohort) control group | 1180 individuals from the general population (Constances' cohort) |
What is being measured
The primary outcome is the main question the study is designed to answer.
proportion of sexual dissatisfaction in women with LS compared with that of women from the general population
proportion of sexual dissatisfaction in women with LS compared to women from the general population (Sexual Life questionnaire from Constances cohort, Questions 'Lifestyle and health: sexual life') in order to compare sexual dissatisfaction in women with LS, on the one hand, and TS, on the other, with that of women from the general population
Measured: Day 0
proportion of sexual dissatisfaction in women with TS compared with that of women from the general population
proportion of sexual dissatisfaction in women with TS compared with that of women from the general population (Sexual Life questionnaire from Constances cohort, Questions 'Lifestyle and health: sexual life') in order to compare sexual dissatisfaction in women with LS, on the one hand, and TS, on the other, with that of women from the general population
Measured: Day 0
Secondary outcomes (17)
proportion of disinterest in sexuality among women with LS compared with that of women from the general population (Sexual Life questionnaire from Constances cohort, Questions 'Lifestyle and health: sexual life')
proportion of disinterest in sexuality among women with LS compared with that of women from the general population (Sexual Life questionnaire from Constances cohort, Questions 'Lifestyle and health: sexual life') in order to compare sexual function, including a lack of interest in sexuality and the occurrence of pain during intercourse, among women with LS, on the one hand, and TS, on the other hand, and women in the general population.
Measured: Day 0
proportion of pain during intercourse in women with LS compared with that of women from the general population (Sexual Life questionnaire from Constances cohort, Questions 'Lifestyle and health: sexual life')
proportion of pain during intercourse in women with LS compared with that of women from the general population (Sexual Life questionnaire from Constances cohort, Questions 'Lifestyle and health: sexual life') in order to compare sexual function, includin
Measured: Day 0
proportion of disinterest in sexuality among women with TS compared with that of women from the general population (Sexual Life questionnaire from Constances cohort, Questions 'Lifestyle and health: sexual life')
proportion of disinterest in sexuality among women with TS compared with that of women from the general population (Sexual Life questionnaire from Constances cohort, Questions 'Lifestyle and health: sexual life') in order to compare sexual function, including a lack of interest in sexuality and the occurrence of pain during intercourse, among women with LS, on the one hand, and TS, on the other hand, and women in the general population.
Measured: Day 0
proportion of pain during intercourse in women with TS compared with that of women from the general population (Sexual Life questionnaire from Constances cohort, Questions 'Lifestyle and health: sexual life')
proportion of pain during intercourse in women with TS compared with that of women from the general population (Sexual Life questionnaire from Constances cohort, Questions 'Lifestyle and health: sexual life') in order to compare sexual function, includin
Measured: Day 0
proportion of women with LS with dysmorphic disorders (Body Dysmorphic Disorder Questionnaire-Aesthetic Surgery)
proportion of women with LS with dysmorphic disorders (Body Dysmorphic Disorder Questionnaire-Aesthetic Surgery) in order to assess body image perceptions among women with LS and TS
Measured: Day 0
proportion of women with TS with dysmorphic disorders (Body Dysmorphic Disorder Questionnaire-Aesthetic Surgery)
proportion of women with TS with dysmorphic disorders (Body Dysmorphic Disorder Questionnaire-Aesthetic Surgery) in order to assess body image perceptions among women with LS and TS.
Measured: Day 0
Body appreciation score (Body Appreciation Scale-2) among women with LS
Body appreciation score (Body Appreciation Scale-2) among women with LS, in order to assess body image perceptions, including body dysmorphic disorders and body appreciation, among women with LS and TS.
Measured: Day 0
Body appreciation score (Body Appreciation Scale-2) among women with TS
Body appreciation score (Body Appreciation Scale-2) among women with TS, in order to assess body image perceptions, including body dysmorphic disorders and body appreciation, among women with LS and TS.
Measured: Day 0
Self-esteem score (Rosenberg Self Esteem Scale) among women with LS
self-esteem score (Rosenberg Self Esteem Scale) among women with LS in order to assess self-esteem among women with LS and TS.
Measured: Day 0
Self-esteem score (Rosenberg Self Esteem Scale) among women with TS
self-esteem score (Rosenberg Self Esteem Scale) among women with TS in order to assess self-esteem among women with LS and TS.
Measured: Day 0
Proportion of gender identity types (Sex, Gender and Sexual orientation) among women with LS
proportion of gender identity types (Sex, Gender and Sexual orientation) among women with LS in order to assess gender identity and sexual orientation among women with LS.
Measured: Day 0
Proportion of sexual orientation types (Sex, Gender and Sexual orientation) among women with LS
Proportion of sexual orientation types (Sex, Gender and Sexual orientation) among women with LS in order to assess gender identity and sexual orientation among women with LS.
Measured: Day 0
Proportion of aesthetic surgery (Reconstructive surgery data collection form, Questions 'Aesthetic surgery') among women with LS
proportion of aesthetic surgery (Reconstructive surgery data collection form, Questions 'Aesthetic surgery') among women with LS in order to assess the use and total cost of aesthetic care
Measured: Day 0
Total Cost of aesthetic care (Reconstructive surgery data collection form, Questions 'Total cost') among women with LS.
Total Cost of aesthetic care (Reconstructive surgery data collection form, Questions 'Total cost') among women with LS in order to assess the use and total cost of aesthetic surgery
Measured: Day 0
Qualitative evaluation of sexual quality of life, self-esteem, body image perceptions and feminity using semi-structured interviews (Semi-structured interview guide) among women in the included LS and TS population
Qualitative evaluation using semi-structured interviews (Semi-structured interview guide) among women with LS and TS in order to conduct a qualitative assessment of the sexual quality of life, self-esteem, perceptions of body image and femininity among women with LS and TS.
Measured: Day 0
proportion of women who sought psychological or psychotherapeutic support (Questionnaire, section 'Psychological Support') among women with LS
proportion of women who sought psychological or psychotherapeutic support (Questionnaire, section 'Psychological Support') among women with LS to assess the use of psychological or psychotherapeutic support aimed at self-acceptance and body acceptance in women with LS and TS.
Measured: Day 0
proportion of women who sought psychological or psychotherapeutic support (Questionnaire, section 'Psychological Support') among women with TS
proportion of women who sought psychological or psychotherapeutic support (Questionnaire, section 'Psychological Support') among women with TS to assess the use of psychological or psychotherapeutic support aimed at self-acceptance and body acceptance in women with LS and TS.
Measured: Day 0
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Sep 2026
- Study start1 Oct 2026 (estimated)
- Primary completion1 Aug 2027 (estimated)
- Study completionMar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lipodystrophy Congenital GeneralizedStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 1,416 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Inès BELALEM, Nurse - Data Manager, PhDs, Principal investigator, Assistance Publique - Hôpitaux de Paris
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07799012
- Sponsor's protocol ID
- APHP251569
- Other IDs
- IDRCB : 2025-A02393-46
- Acronym
- LIPTURN
- Status last verified
- Aug 2026
- First submitted
- 28 Aug 2026
- Last updated
- 2 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 2 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Sexual Quality of Life in Female Patients With Lipodystrophy Syndromes or Turner Syndrome: a Case-control Study
- ClinicalTrials.gov ID
- NCT07799012
- Acronym / sponsor ID
- LIPTURN / APHP251569
- Keywords
- Lipodystrophy, Turner Syndrome, Sexual Health, Quality of Life, Body Image, Body Satisfaction, Body Dissatisfaction
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 1,416 participants (estimated)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Study start
- 1 Oct 2026 (estimated)
- Primary completion
- 1 Aug 2027 (estimated)
- Study completion
- Mar 2028 (estimated)
- First posted
- 2 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Turner syndrome (TS) and congenital lipodystrophy syndromes (LS) are rare conditions with major consequences on cardiometabolic health, fertility, and body morphology. Some physical changes are visible from childhood in women with TS and from puberty in women with LS. Frequently, body morphology constitutes the first symptom orienting the diagnosis.
In 2018, a systematic review identified 13 studies (4 randomised controlled trials, 1 case-control study, 4 cohort studies, 4 cross-sectional studies) assessing quality of life in women with TS and two observational studies in women with LS (1 cohort study, 1 cross-sectional study). These investigations suggested an impairment in the overall quality of life compared with the general population.
However, little data exists on sexual quality of life, which is influenced by various factors: biological, hormonal, developmental, psychological, relational and social determinants. In the context of these chronic conditions, with biological and hormonal determinants, sexual quality of life may be affected.
Only three observational studies assessing sexual quality of life with small sample sizes, including one ongoing study, have been identified. Data suggested a decrease in the sexual quality of life.
When integrated into women's care pathways, aesthetic care recommended in French national diagnostic and management plans may help improving body image in women with LS. The uptake of these treatments in line with the recommendations has never been assessed, nor have their costs.
This study aims to compare the sexual quality of life of women with TS or LS with that of the general population.
Detailed description
Turner syndrome (TS) and congenital lipodystrophy syndromes (LS) are rare conditions with major consequences on cardiometabolic health, fertility, and body morphology. Certain physical changes are visible from childhood in women with TS and from puberty in women with LS. Frequently, body morphology constitutes the first symptom orienting the diagnosis.
In 2018, a systematic review identified 13 studies (4 randomised controlled trials, 1 case-control study, 4 cohort studies, 4 cross-sectional studies) assessing quality of life in women with TS and two observational studies in women with LS (1 cohort study, 1 cross-sectional study). These investigations suggested an impairment in the overall quality of life compared with the general population.
However, little data exists on sexual quality of life, which is influenced by various factors: biological, hormonal, developmental, psychological, relational and social determinants. In the context of these chronic conditions, with biological and hormonal determinants, sexual quality of life may be affected.
Only three observational studies assessing sexual quality of life with small sample sizes, including one ongoing study, have been identified. Data suggested a decrease in the sexual quality of life.
In a 2013 cohort study of 26 sexually active women with TS, reduced arousal was found. A cross-sectional study involving 46 women with LS suggested that 42% of women were dissatisfied with their sex lives. A cross-sectional study comparing the sexual function of 99 women with TS and premature ovarian failure to that of 106 women with premature ovarian failure without TS showed that women with LS had less frequent sexual intercourse, a later age at first intercourse, a lower number of sexual partners and less frequent orgasms.
When integrated into women's care pathways, aesthetic care recommended in French national diagnostic and management plans may help improving body image in women with LS. The uptake of these treatments in line with the recommendations has never been assessed, nor have their costs.
This study aims to compare the sexual quality of life of women with TS or LS with that of the general population.
The hypothesis is that sexual quality of life is poorer in women with TS or LS than in the general population.
Perceptions of body image, the use of aesthetic care and their costs will also be described to assess the implementation of recommendations and to develop potential avenues for care or improvement, if necessary, in the management of these patients.
Sample size:
We aim to test two hypotheses concerning the two populations (LS and TS) compared with controls from the general population, for whom the proportion of sexual dissatisfaction is estimated at 27.5%. Assuming a proportion of dissatisfaction at least 20% higher in both patient groups, with a two-sided alpha of 2.5%, a power of 80%, and Fisher's exact test, 118 women with LS, 118 women with TS, and 590 + 590 matched controls (planned ratio 1:5) will be required, for a total of 1,416 participants.
The qualitative interviews will be proposed to 20 women (10 LS and 10 TS), selected purposively according to age, study center, and investigators' judgment.
Study procedures:
Quantitative phase:
An information sheet will be sent by post, accompanied by an explanatory letter from the patient's doctor, and a telephone consultation will be arranged with the study coordinator at each centre to document non-opposition from all patients meeting the inclusion criteria. A reflection period of 5 to 10 minutes will be allowed. The non-opposition will be recorded in the medical record.
Patients have a 14-day period to complete the questionnaires at home using an e-CRF. The time required to complete the questionnaires is estimated at approximately 30 minutes.
In the event of non-response, reminders will be sent by email on Day 15, followed by a telephone call on Day 21. Patients hospitalized or attending outpatient consultations in participating centres during the recruitment period will also be invited to participate, if they have not already completed the questionnaires.
Qualitative phase:
Following questionnaire completion, and approval of the study coordinator for the centre, an information sheet accompanied by an explanatory letter from the patient's doctor, will be sent by post to a sample of 20 women, and a telephone consultation will be arranged to invite them to take part in the qualitative study.
Semi-structured interviews of 45 minutes will be conducted remotely or in person during hospitalisations or outpatients' consultations in the Endocrinology Department, Saint Antoine Hospital, AP-HP, by the coordinating investigator within two months of documented non-opposition.
Study duration:
- Inclusion period: 14 months (quantitative phase: 9 months; qualitative phase: 5 months)
- Individual participation period: maximum of 2 months and 28 days (quantitative phase: maximum of 28 days; qualitative phase: maximum of 2 months)
- Total study duration: 16 months + 28 days
Number of centers: 3
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Lipodystrophy syndromes group | – | –118 patients with lipodystrophy syndromes |
| Turner syndrome group | – | –118 patients with Turner syndrome |
| General population (Constances' cohort) control group | – | –1180 individuals from the general population (Constances' cohort) |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult women with genetically confirmed lipodystrophy syndromes [Congenital Generalized] or [Partial Familial] or Turner syndrome, and with at least one consultation in the participant centers.
Key inclusion criteria (8 listed)
- Female aged 18 or more
- Diagnosed with LS (Congenital Generalized Lipodystrophy or Familial Partial Lipodystrophy) or TS, diagnosis genetically confirmed
- Patients followed in one of the participating centers
- Adequate written and oral comprehension of the French language
- No objection to participate
Key exclusion criteria (1 listed)
- Not applicable
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
proportion of sexual dissatisfaction in women with LS compared with that of women from the general population
Time frame: Day 0
proportion of sexual dissatisfaction in women with LS compared to women from the general population (Sexual Life questionnaire from Constances cohort, Questions 'Lifestyle and health: sexual life') in order to compare sexual dissatisfaction in women with LS, on the one hand, and TS, on the other, with that of women from the general population
proportion of sexual dissatisfaction in women with TS compared with that of women from the general population
Time frame: Day 0
proportion of sexual dissatisfaction in women with TS compared with that of women from the general population (Sexual Life questionnaire from Constances cohort, Questions 'Lifestyle and health: sexual life') in order to compare sexual dissatisfaction in women with LS, on the one hand, and TS, on the other, with that of women from the general population
17 secondary outcomes
proportion of disinterest in sexuality among women with LS compared with that of women from the general population (Sexual Life questionnaire from Constances cohort, Questions 'Lifestyle and health: sexual life')
Time frame: Day 0
proportion of pain during intercourse in women with LS compared with that of women from the general population (Sexual Life questionnaire from Constances cohort, Questions 'Lifestyle and health: sexual life')
Time frame: Day 0
proportion of disinterest in sexuality among women with TS compared with that of women from the general population (Sexual Life questionnaire from Constances cohort, Questions 'Lifestyle and health: sexual life')
Time frame: Day 0
proportion of pain during intercourse in women with TS compared with that of women from the general population (Sexual Life questionnaire from Constances cohort, Questions 'Lifestyle and health: sexual life')
Time frame: Day 0
proportion of women with LS with dysmorphic disorders (Body Dysmorphic Disorder Questionnaire-Aesthetic Surgery)
Time frame: Day 0
proportion of women with TS with dysmorphic disorders (Body Dysmorphic Disorder Questionnaire-Aesthetic Surgery)
Time frame: Day 0
Body appreciation score (Body Appreciation Scale-2) among women with LS
Time frame: Day 0
Body appreciation score (Body Appreciation Scale-2) among women with TS
Time frame: Day 0
Self-esteem score (Rosenberg Self Esteem Scale) among women with LS
Time frame: Day 0
Self-esteem score (Rosenberg Self Esteem Scale) among women with TS
Time frame: Day 0
Proportion of gender identity types (Sex, Gender and Sexual orientation) among women with LS
Time frame: Day 0
Proportion of sexual orientation types (Sex, Gender and Sexual orientation) among women with LS
Time frame: Day 0
Proportion of aesthetic surgery (Reconstructive surgery data collection form, Questions 'Aesthetic surgery') among women with LS
Time frame: Day 0
Total Cost of aesthetic care (Reconstructive surgery data collection form, Questions 'Total cost') among women with LS.
Time frame: Day 0
Qualitative evaluation of sexual quality of life, self-esteem, body image perceptions and feminity using semi-structured interviews (Semi-structured interview guide) among women in the included LS and TS population
Time frame: Day 0
proportion of women who sought psychological or psychotherapeutic support (Questionnaire, section 'Psychological Support') among women with LS
Time frame: Day 0
proportion of women who sought psychological or psychotherapeutic support (Questionnaire, section 'Psychological Support') among women with TS
Time frame: Day 0
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Sep 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Lipodystrophy Congenital Generalized
Active, not recruitingPhase 3
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
Lipodystrophy, Diabetes
RecruitingPhase 3
Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy
Generalized Lipodystrophy
RecruitingObservational study
MEASuRE: Metreleptin Effectiveness And Safety Registry
Generalised Lipodystrophy, Partial Lipodystrophy
RecruitingPhase 1/2
64Cu-GRIP B in Patients With Advanced Malignancies
Prostate Cancer, Renal Cancer
RecruitingObservational study
Registry for Patients With Lipodystrophy
Lipodystrophy Acquired, Lipodystrophy Congenital
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Judith LEBLANC, Nurse, Associate professor SU contact
Inès BELALEM, Nurse - Data Manager, PhDs principal investigator
Assistance Publique - Hôpitaux de Paris
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lipodystrophy Congenital Generalized and Lipodystrophy, Familial Partial, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Inès BELALEM, Nurse-Data manager-PhDs (00 33 149282401, Ines.belalem@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
proportion of sexual dissatisfaction in women with LS compared with that of women from the general population (time frame: Day 0). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2026.